Drug reference
interferon beta
Cytokine · Immunomodulator
CytokineImmunomodulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Endogenous regulatory cytokines that increase or decrease transcriptional initiation of hundreds of genes in a cell-dependent fashion with multiple mechanisms of action, including induction of IL-10.
Indications
autoimmune diseases, particularly ms (decreasing exacerbation rate by ~30%)
Dosing
- Adult
- administered either by the intramuscular or subcutaneous routes
Pharmacokinetics
Bioavailability
SC: 51 ± 17%
Protein binding
—
Excretion
—
Side effects
Common
fatigue
Related guidelines
Glomerular diseases
KDIGO · Nephrology · 2021
Sjögren's syndrome
EULAR · Rheumatology · 2025
Extrapulmonary tuberculosis
ICMR · Infectious Diseases · 2022
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Other Cytokine drugs
Ask House about interferon beta
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10